Project Grant R01CA283394
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$599K
Federal Agency
National Cancer Institute
Awardee
Purdue University (YRXVL4JYCEF5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
West Lafayette, IN 47907, USA
Similar Awards
This $1,130,538 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to target the tumor-specific Tn antigen in pancreatic ductal adenocarcinoma (PDAC). The University of Louisville, as the prime awardee, will: Determine how the Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins using mouse models and clinical specimens. Validate the role of natural killer cells in the...
This $432,889 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to advance molecular imaging and metabolic therapies for reversing cachexia induced by pancreatic ductal adenocarcinoma (PDAC). The research team at The Johns Hopkins University will focus on disrupting glutamine metabolism in PDAC models, studying the effects on tumor and organ metabolism, as well as changes in the tumor and spleen immune...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $627,272 to The Johns Hopkins University to optimize the efficacy of chimeric antigen receptor (CAR) T cells against pancreatic tumors. The researchers will engineer synthetic cytokine receptors (called "Velocity Receptors") on the CAR T cells to enhance their migration speed and tumor infiltration. They will test the motility and cell-killing capability of these engineered...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research into pancreatic cancer using patient-derived xenograft (PDX) tumor models. The $654,197 award to The General Hospital Corporation (Massachusetts General Hospital) aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how different stromal...
This $1,271,498 federal Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports research to develop a transgenic porcine model of pancreatic cancer for testing novel neoadjuvant therapies and endoscopic medical devices. The award recipient, the University of Nebraska Medical Center (UNMC), will leverage the size advantage of the porcine model to conduct studies that would not be feasible in mice. The overarching goal is to create a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $616,495 to The University of Texas M.D. Anderson Cancer Center to investigate the role of sulfatide metabolism in pancreatic cancer precursor lesions. The key objectives are to: Define the biological functions of sulfatides in the development and progression of pancreatic cancer precursor lesions, such as intraductal papillary mucinous neoplasm (IPMN). This will involve using...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $641,936 to Purdue University to develop a novel in vivo neutrophil programming platform for Chimeric Antigen Receptor (CAR) neutrophil immunotherapy to treat glioblastoma. The award period is from April 2025 to March 2030. The key products and services under this grant include: Developing and optimizing neutrophil-specific CAR constructs using machine learning...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The key objectives are to: 1) explore the role of the lysosomal hydrolase PLBD1 in supporting pancreatic cancer cell metabolism and growth, 2) dissect how the lysosomal hydrolase LGMN enables...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel "armored" CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to engineer CAR-T cells that target the MUC16 antigen on PDAC cells and secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment. The two-phase project will first validate the VIP...
This $622,984 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support a research initiative at the University of California, Los Angeles (UCLA) to develop a non-invasive imaging approach for phenotyping pancreatic ductal adenocarcinoma (PDAC). The research aims to characterize the PDAC tumor microenvironment and tumor-stroma interface at the cellular and tissue levels, enabling assessment of glycolytic and inflammatory...